BCL6 and neoplasm: Second, the disadvantage of this study is that only one OCI-Ly8 cells was used in in vivo study, more DLBCL cells, such as OCI-Ly10 and SUDHL-10, are needed to further confirm the capacity of iRGD-Exo-BCL6 siRNA1 to suppress tumor growth in vivo.